A study evaluating predictive value of PD-L1 immunohistochemistry in patients with non small cell lung cancer treated with Nivolumab.
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 11 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress